Embera Pharma

Embera NeuroTherapeutics is a private clinical-stage specialty pharmaceutical company developing treatments for substance use disorders and addiction. Its lead and apparently sole disclosed program is EMB-001, an oral fixed-dose combination of metyrapone and oxazepam designed to modulate stress-response and craving pathways involved in relapse. The company has advanced EMB-001 into Phase 2 development for cocaine use disorder and has also studied it in smoking cessation/tobacco use disorder. Embera has described its focus as cocaine, nicotine, and potentially other addictions, and it has licensed key EMB-001 technology from LSU Health Sciences Center Shreveport. The business appears centered on repurposed small-molecule combination therapy rather than a broad discovery platform.